Social fitness: hype and hard claims

A fitness post telling people that losing fat while gaining muscle is hard is broadly in line with sports-medicine guidance; a separate viral cancer post about ivermectin is not backed by comparable human evidence. (acsm.org) The muscle-and-fat idea is called body recomposition: adding lean tissue while reducing body fat at the same time. The American College of Sports Medicine said on March 17, 2026 that regular resistance training, done at least twice a week for major muscle groups, is the main driver for muscle gain, and that consistency matters more than complex programming. (acsm.org) That makes “really hard” a fair description for many adults, especially trained lifters, because muscle growth usually needs enough training volume, protein, and recovery while fat loss usually needs a calorie deficit. The American College of Sports Medicine’s 2026 evidence review drew on 137 systematic reviews covering more than 30,000 participants and said outcomes should be individualized rather than built around one “perfect” plan. (acsm.org) The ivermectin post rests on a very different kind of evidence. The numbers spreading online — 197 patients, an 84 percent “clinical benefit ratio,” 48 percent reporting regression or no evidence of cancer, and 36 percent reporting stable disease after six months — come from an April 7, 2026 news release by The Wellness Company about a manuscript it said was still under peer review. (twc.health) That release said patients took compounded capsules containing 25 milligrams of ivermectin and 250 milligrams of mebendazole, another anti-parasitic drug. It also said outcomes were self-reported in a “prospective real-world cohort” covering many cancer types, which means the figures were not presented as results from a randomized head-to-head trial against chemotherapy. (twc.health) The National Cancer Institute does list ivermectin in its drug dictionary and has hosted cancer trials that included it, which shows researchers have explored the drug in oncology. But one National Cancer Institute phase two study of ivermectin plus pembrolizumab in metastatic triple-negative breast cancer is listed as withdrawn, not completed with efficacy results. (cancer.gov; cancer.gov) Published reviews do not treat ivermectin as a proven cancer therapy in people. A 2025 review in *Gynecologic Oncology Reports* said clinical studies in cancer are limited, data in gynecologic cancers are lacking, and the authors “strongly caution” against using ivermectin to treat those cancers outside proper evidence-based care. (pubmed.ncbi.nlm.nih.gov) The Food and Drug Administration approves ivermectin in humans for specific parasitic infections and some topical skin uses, not for cancer. The agency also says high doses can be dangerous and that ivermectin can interact with other medicines, including blood thinners. (fda.gov) Fact-checkers have already pushed back on broader social posts claiming ivermectin can outperform chemotherapy. Australian Associated Press FactCheck reported this week that lab findings do not establish human benefit and that experts said clinical trials are still needed before ivermectin can be judged effective against cancer. (aap.com.au) So the two viral messages are not on the same footing. One compresses established training advice into a blunt slogan; the other turns an unpublished, self-reported observational report into a claim about matching chemotherapy, a standard the available public evidence does not meet. (acsm.org; twc.health; pubmed.ncbi.nlm.nih.gov)